The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent bispecific antibody designed to suppress the PD-1 pathway and provide modulated CTLA4 inhibition favoring enhanced blockade on PD-1^+ activated T cells. We show that MEDI5752 preferentially saturates CTLA4 on PD-1^+ T cells versus PD-1^- T cells, reducing the dose required to elicit IL2 secretion. Unlike conventional PD-1/CTLA4 mAbs, MEDI5752 leads to the rapid internalization and degradation of PD-1. Moreover, we show that MEDI5752 preferentially localizes and accumulates in tumors providing enhanced activity when compared with a combination of mAbs targeting PD-1 and CTLA4 in vivo. Following treatment with MEDI5752, robust partial responses were observed in two patients with advanced solid tumors. MEDI5752 represents a novel immunotherapy engineered to preferentially inhibit CTLA4 on PD-1^+ T cells.

**Significance:** The unique characteristics of MEDI5752 represent a novel immunotherapy engineered to direct CTLA4 inhibition to PD-1^+ T cells with the potential for differentiated activity when compared with current conventional mAb combination strategies targeting PD-1 and CTLA4. This molecule therefore represents a step forward in the rational design of cancer immunotherapy.

See related commentary by Burton and Tawbi, p. 1008.
INTRODUCTION

Immune checkpoint blockade (ICB) is now an established part of the standard of care for a broad range of tumor types (1). To date, regulatory approvals center on two key coinhibitory pathways: PD-1 and CTLA4 (2). Moreover, a combination of PD-1 and CTLA4 blockade has been shown to improve overall survival and is approved for the treatment of advanced melanoma, renal cell carcinoma (RCC), and non–small cell lung cancer (NSCLC; refs. 3–6). However, although a dose-dependent response has been observed clinically for anti-CTLA4 mAb, the therapeutic dose is limited due to immune-related adverse events (irAE; refs. 7, 8). Therefore, novel approaches to facilitate enhanced CTLA4 blockade, in combination with a PD-1 mAb, are urgently needed.

The coinhibitory molecule PD-1 is induced following T-cell activation with expression maintained via repeated signaling through the T-cell receptor (TCR). As a consequence, PD-1 is a marker of tumor-associated antigen–specific tumor-infiltrating lymphocytes (TIL; ref. 9). Signaling through PD-1 via binding to PD-L1 and PD-L2 can negatively regulate T-cell responses both by attenuating TCR signaling (10, 11) and through dephosphorylation of the costimulatory receptor CD28 (12, 13). Blockade of this signaling axis leads to reinvigoration of T-cell function and effective antitumor responses.

CTLA4 is a coinhibitory molecule that is rapidly upregulated following TCR engagement (14). CTLA4 binds to the coactivatory receptors CD80 and CD86 expressed on antigen-presenting cells with higher affinity than CD28, thereby regulating T-cell activation and function via modulation of the amplitude of signaling through the TCR/MHC complex (15–20). In addition, CTLA4 can also function through a cell-extrinsic mechanism by limiting the availability of CD80/CD86 either through competition or by ligand transendoctyosis, owing to the rapid turnover of the receptor from the plasma membrane to intracellular vesicles (21). CTLA4 expression is elevated on tumor-infiltrating regulatory T cells (Treg) and on subpopulations of antigen-experienced/exhausted effector T (Teff) cells when compared
with peripheral T-cell populations (22–24). Therefore, CTLA4 functions to regulate the provision of costimulatory signaling through CD28, affecting both initial T-cell priming and activity of antigen-experienced T cells (16, 24, 25).

Interestingly, previous studies have demonstrated that tumor-resident PD-1+ effector memory T cells are associated with response to PD-1 monotherapy and combined PD-1/CTLA4 therapy (26, 27). Moreover, several preclinical studies demonstrate that local administration of anti-CTLA4 mAb into the tumor or administration of a prodrug that is rendered active in the tumor microenvironment (TME) is sufficient for mediating antitumor activity and is commensurate with reduced peripheral immune activation versus systemic administration and may therefore be used in an attempt to uncouple antitumor activity from potential irAEs (28–36).

Supporting this, early diversification of the TCR repertoire following CTLA4 blockade has been associated with irAEs, suggesting that peripheral blockade of this pathway may contribute to its toxicity profile through the activation of new T-cell clones (37, 38).

MEDI5752 has been designed to suppress signaling through the PD-1 axis and provide preferential inhibition of CTLA4 on activated PD-1+ T cells when compared with PD-1− T-cell populations. Here, we show that MEDI5752 can saturate CTLA4 on PD-1+ cells at orders of magnitude lower concentrations than required to saturate CTLA4 on PD-1− cells. Specifically, in a range of in vitro assays, we show that MEDI5752 can enhance T-cell activity when compared with a combination of mAbs targeting the PD-1 and CTLA4 pathways. Furthermore, when compared with a combination of mAbs, we show that MEDI5752 can preferentially accumulate in the TME and generate effective antitumor immune responses in humanized mice. Moreover, we show that by tethering CTLA4 to PD-1, MEDI5752 leads to the internalization and subsequent degradation of PD-1. Collectively, these novel mechanisms of action may allow for effective blockade of the PD-1 axis while providing enhanced CTLA4 inhibition in the TME than can be achieved versus conventional mAb-based combinatorial approaches. To support the translational nature of our work, we present illustrative evidence of clinical activity in two patients treated with MEDI5752 from an ongoing phase I study in advanced solid tumors (NCT03530397).

RESULTS

Expression of CTLA4 on TILs Is Enriched on PD-1+ T Cells across a Range of Solid Tumors

PD-1 and CTLA4 expression on TILs from 44 disaggregated tumors (ICB-naïve) across four indications (colorectal cancer, NSCLC, RCC, and melanoma) were profiled by flow cytometry. These data revealed that PD-1/CTLA4 double-positive CD4+ and CD8+ T cells could be found across all tumor types and that expression of CTLA4 was enriched on PD-1+ T cells (Fig. 1A and B; Supplementary Fig. S1A and S1B). Moreover, we show that CD39 expression, a marker for tumor-reactive CD8+ T cells (39), was enriched on these PD-1+CTLA4+ TILs (Fig. 1C). We then used coc cryostat analysis on sequential tissue sections to further interrogate PD-1 and CTLA4 expression on TILs from 183 tumors across squamous cell carcinoma of the head and neck (SCCHN), NSCLC, and urothelial cell carcinoma (UCC). These data demonstrated that 80% SCCHN, 84% squamous cell NSCLC, 89% adenocarcinoma NSCLC, and 90% UCC profiled in these indications are infiltrated by TILs coexpressing PD-1 and CTLA4 (Fig. 1D and E). Based on these expression data, we generated a novel bispecific antibody that could cotarget PD-1 and CTLA4.

Design and Characterization of a Monovalent Bispecific Antibody Targeting PD-1 and CTLA4

The variable domains of tremelimumab (anti-CTLA4) and an anti–PD-1 mAb were formatted onto a DuetMab backbone (40). The human gamma-1 constant heavy chain was further engineered to carry the triple mutations (L234F, L235E, and P331S) designed to reduce fragment crystallizable (Fc)–mediated immune effector functions (41). The corresponding anti–PD-1/CTLA4 monovalent bispecific DuetMab was designated MEDI5752. The intrinsic binding kinetics of MEDI5752 for recombinant human, cynomolgus monkey, and murine PD-1 and CTLA4 antigens were determined by surface plasmon resonance. The PD-1 and CTLA4 arms of MEDI5752 maintain the intrinsic binding affinity of the parental mAbs from which they were derived. Consistent with the binding properties of the two parental mAbs, MEDI5752 exhibits only residual binding to the murine ortholog of PD-1 and shows no cross-reactivity to murine CTLA4 (Supplementary Fig. S2). The ability of MEDI5752 to concurrently bind recombinant human and cynomolgus monkey PD-1 and CTLA4 proteins was determined by Octet analysis (Supplementary Fig. S3A and S3B). Guided by expression data from TILs (Supplementary Fig. S4), we generated engineered Chinese hamster ovary (CHO) cell lines expressing either PD-1, CTLA4, or a combination of receptors where PD-1 was in approximately 10- or 40-fold excess of CTLA4 (Supplementary Fig. S5). We show that MEDI5752 maintains the binding properties of parental anti–PD-1 and anti-CTLA4 mAbs to their respective target receptors on CHO cells (Supplementary Fig. S6A–S6D) and on stimulated CD4+ and CD8+ T cells (Supplementary Fig. S7A–S7D). We then confirmed that MEDI5752 was able to concurrently bind PD-1 and CTLA4 receptors on the surface of the same cell and thereby was able to mediate cross-arm avidity binding (Supplementary Fig. S8A and S8B).

Valence Affects CTLA4 Inhibition but Has Minimal Impact on PD-1

We determined how valence would affect PD-1 and CTLA4 receptor inhibition using two-cell luciferase reporter...
Modulated CTLA4 Inhibition via Preferential Binding to PD-1

**A**

![Graphs showing percentage of Total CD4+ T cells and CD8+ T cells across different cancer types](image)

**B**

<table>
<thead>
<tr>
<th></th>
<th>CD4+ T cells</th>
<th>CD8+ T cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRC</td>
<td>3.77</td>
<td>42.2</td>
</tr>
<tr>
<td>NSCLC</td>
<td>2.67</td>
<td>24.6</td>
</tr>
<tr>
<td>RCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanoma</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**C**

![Images of scatter plots showing PD-1 and CTLA4 expression](image)

**D**

<table>
<thead>
<tr>
<th></th>
<th>SCCHN</th>
<th>NSCLC-Sq</th>
<th>NSCLC-Ad</th>
<th>UCC</th>
</tr>
</thead>
<tbody>
<tr>
<td>High number of double positives</td>
<td>17%</td>
<td>45%</td>
<td>35%</td>
<td>32%</td>
</tr>
<tr>
<td>Low number of double positives</td>
<td>63%</td>
<td>39%</td>
<td>54%</td>
<td>58%</td>
</tr>
<tr>
<td>Double positive unlikely/undetected</td>
<td>20%</td>
<td>16%</td>
<td>11%</td>
<td>10%</td>
</tr>
</tbody>
</table>

**E**

![Images of PD-1 and CTLA4 expression in cancer tissues](image)
assays. The switch to monovalent targeting of PD-1 as either MEDI5752 or a monovalent PD-1 (mPD-1) had limited impact (3.5- and 3.8-fold, respectively) on potency when compared with a bivalent anti–PD-1 mAb (Fig. 2A and B). In comparison, monovalent targeting of CTLA4 with either MEDI5752 or a monovalent CTLA4 (mCTLA4) resulted in a 14.9- and 13.3-fold reduction in potency respectively when compared with a bivalent CTLA4 mAb (Fig. 2C and D). Next, we tested the functional consequence of monovalent targeting of PD-1 in a peripheral blood mononuclear cell (PBMC) assay. In agreement with the two-cell reporter assay, these data showed that valence had little effect on PD-1 inhibition [1.14-fold difference in minimum effective concentration (MEC) required to induce a 2-fold increase in IL2 secretion from PBMC; Fig. 2E and F]. However, valence had a significant impact when targeting CTLA4, with an 8.1-fold increase in the concentration of an mCTLA4 required to induce this increase in IL2 secretion from PBMC when compared with a bivalent molecule (Fig. 2G and H). These results demonstrate that valence is important for effective functional CTLA4 blockade and that MEDI5752 binding/inhibition of CTLA4 may be significantly weaker on PD-1+ T cells.

**MEDI5752 Preferentially Inhibits CTLA4 on PD-1+ Cells**

In the case of bispecific antibodies targeting two distinct cell-surface antigens, the relative density of the two receptors has a strong effect on the binding kinetics (42). The bispecific antibody is predisposed to bind first to the more highly expressed receptor as a function of its abundance; hence, the occupancy of the predominant receptor will depend only on the intrinsic binding affinity of the monovalent arm to that receptor. Upon binding of the first arm, the unbound arm is now confined to a limited hemispheric space with a radius equal to the length of the antibody. Consequently, the effective concentration of the less predominant receptor in this constrained volume dramatically increases, and as a result the binding kinetics of the second arm is significantly enhanced. We define the binding mode of the second arm as “cooperative binding” (Fig. 3A). Thus, the occupancy of the less highly expressed receptor is likely to occur at progressively lower concentrations of the bispecific antibody and may exceed the intrinsic affinity of the antibody–antigen interaction by orders of magnitude. The magnitude of this effect appears proportional to the receptor ratio. Given the higher receptor density of PD-1 over CTLA4 on double-positive T cells, the ability of MEDI5752 to preferentially target and saturate CTLA4 on CHO PD-1+ CTLA4+ cells, compared with CHO PD-1+ CTLA4+ cells expressing only CTLA4, was tested. MEDI5752 saturated the CTLA4 receptor on CHO PD-1+ CTLA4+ (10:1) and CHO PD-1+ CTLA4+ (40:1) cells at approximately 40- and 500-fold lower concentration, respectively, compared with CHO PD-1+ CTLA4+ cells expressing only CTLA4 (Fig. 3B; Supplementary Fig. S9). Next, we tested the functional consequence of cooperative binding of MEDI5752 to PD-1/CTLA4 double-positive cells. To model this, primary human PBMCs were preincubated with or without saturating doses of anti–PD-1, generating model CTLA4 single-positive and PD-1/CTLA4 double-positive cells. Conceptually MEDI5752 will bind to PD-1 preblocked PBMC only via freely available CTLA4; however, on non-preblocked PBMC, MEDI5752 will bind preferentially and facilitate augmented activity. These data showed that cooperative binding reduces the MEC of MEDI5752 required to induce a 3-fold increase in IL2 secretion from anti-CD3 and Staphylococcal Enterotoxin B (SEB)-stimulated PBMC by 93.55-fold (Fig. 3C and D). These results suggest that MEDI5752 can preferentially inhibit CTLA4 on PD-1+ activated versus nonactivated T cells.

**MEDI5752 Leads to the Internalization and Degradation of PD-1**

The CTLA4 receptor has been reported to rapidly internalize from the plasma membrane in a clathrin- and dynamin-dependent manner driven by the well-characterized YVKM trafficking motif, resulting in only a small fraction of the receptor presented on the cell surface at any given time (20). It was further estimated that more than 80% of cell-surface CTLA4 is internalized within 5 minutes at steady state (24). As such, the internalization properties of MEDI5752 and parental mAbs into CHO PD-1+ CTLA4+ (10:1) cells and stimulated primary human CD4+ and CD8+ T cells were interrogated. These data showed that both MEDI5752 and anti-CTLA4 mAb rapidly internalized, whereas anti-PD-1 mAb showed limited internalization (Fig. 4A–E). We next demonstrated that upon concurrent cellular binding and internalization, MEDI5752 induced a dose- and time-dependent downregulation of cell-surface PD-1 in CHO PD-1+ CTLA4+ (10:1) cells, promoting more than 90% receptor downregulation after 6 hours of incubation (Supplementary Fig. S10). In contrast, under the same conditions, the parental anti-PD-1 mAb mediated only moderate receptor downregulation (Supplementary Fig. S10). Similarly, cell-surface PD-1 downregulation was observed on both CD4+ and CD8+ T cells after MEDI5752 treatment (Supplementary Fig. S11A–S11D). Removal of MEDI5752 from the culture media led to recovery of cell-surface PD-1 on both CD4+ and CD8+ T cells (Supplementary Fig. S11). Collectively, these data indicate that both MEDI5752 and anti-CTLA4 mAbs efficiently internalized into CHO PD-1+ CTLA4+ cells and stimulated CD4+ and CD8+ T cells.

To access the fate of the PD-1 and CTLA4 receptors upon concurrent cellular binding and internalization of MEDI5752, PD-1+SNAPl-tag/CTLA4+CLIP-tag double-positive CHO cells were generated. MEDI5752 induced the colocalization of PD-1 and CTLA4 receptors; conversely, parental mAbs resulted in no change in colocalization (Supplementary Fig. S12A and S12B). Furthermore, PD-1 and CTLA4 receptors also colocalize with lysosomes upon MEDI5752 treatment (Supplementary Fig. S12C–S12E). Notably, PD-1+SNAPl-tag/CTLA4+CLIP-tag double-positive CHO cells (Fig. 4F–H) and stimulated CD4+ and CD8+ T cells (Fig. 4I) treated with MEDI5752 showed profound degradation of cell-surface PD-1 receptor. None of the treatments altered CTLA4 receptor internalization, with approximately 50% of the receptor internalized within 3 to 5 hours (Fig. 4F–H). Notably, degradation of cell-surface PD-1 was dependent upon concurrent binding to recycling CTLA4, as no degradation of PD-1 was induced when MEDI5752 was incubated with the single-positive CHO PD-1+ CTLA4+ cells or when the double-positive CHO PD-1+ CTLA4+ (10:1) cells were treated with the parental anti–PD-1 (Supplementary Fig. S13A–S13C). Furthermore, given MEDI5752 levels were maintained after

---

1104 | CANCER DISCOVERY  MAY 2021  AACRJournals.org

Downloaded from cancerdiscovery.aacrjournals.org on December 6, 2021. © 2021 American Association for Cancer Research.
Figure 2. Monovalent targeting reduces the potency of MEDI5752 against CTLA4 but has minimal impact on PD-1. A and B, Two-cell luciferase reporter assay whereby CHO cells engineered to express PD-L1 and anti-CD3 (OKT3) are cocultured with Jurkat cells engineered to overexpress PD-1. The addition of anti-PD-1 targeting molecules blocks the inhibitory signal mediated via PD-1/PD-L1 interactions facilitating NFAT activation and luciferase gene expression. MEDI5752, anti-PD-1, mPD-1, and isotype mAbs are added to this coculture, and luciferase expression is detected by Steady-Glo Luciferase assay after 6-hour incubation (n = 3, representative example displayed). RLU, relative light units. B, Potency was calculated by comparing EC50 values of MEDI5752 and mPD-1 with the EC50 value of anti-PD-1. C and D, Two-cell luciferase reporter assay whereby Raji cells expressing CD80 and CD86 are cocultured with Jurkat cells engineered to overexpress CTLA4 with anti-CD3. The addition of anti-CTLA4 targeting molecules blocks the inhibitory signal mediated via CTLA4/CD80/CD86 interactions, facilitating IL2 activation and luciferase gene expression. MEDI5752, anti-CTLA4, mvCTLA4, and isotype mAbs are added to this coculture, and luciferase expression is detected by Steady-Glo Luciferase assay after 6-hour incubation (n = 3, representative example displayed). D, Potency was calculated by comparing EC50 values of MEDI5752 and mvCTLA4 with the EC50 value of anti-CTLA4.

E and F, Human PBMCs were stimulated with cytostim in the presence of bivalent anti–PD-1 or mPD-1 for 72 hours, and IL2 secretion was measured by ELISA (n = 9, independent donors). G and H, Human PBMCs were stimulated with cytostim plus LPS in the presence of bivalent anti-CTLA4 or mvCTLA4 for 72 hours, and IL2 secretion was measured by ELISA (n = 9, independent donors). F and H, The MEC required to induce a 2-fold increase in IL2 secretion from baseline was calculated.

Cancer Research. Published OnlineFirst January 8, 2021; DOI: 10.1158/2159-8290.CD-20-1445
**Figure 3.** MEDI5752 preferentially targets CTLA4 on double-positive versus single-positive cells.  
**A,** Diagram representing the binding profile of MEDI5752 to either PD-1⁻/CTLA4⁺ single-positive cells simulating the periphery or PD-1⁺/CTLA4⁺ double-positive cells simulating the tumor. **B,** CHO cell receptor occupancy assay where MEDI5752 was incubated on either PD-1⁻/CTLA4⁺ single-positive or PD-1⁺/CTLA4⁺ double-positive CHO cells and MEDI5752 binding was assessed by flow cytometry. **C and D,** Human PBMC were stimulated with anti-CD3 and SEB in the presence of MEDI5752 with or without anti-PD-1 preblock for 72 hours, and IL2 secretion was measured by ELISA (n = 8, independent donors). **D,** The MEC required to induce a 3-fold increase in IL2 secretion from baseline was calculated. MFI, mean fluorescence intensity.
Figure 4. MEDI5752 leads to the internalization and degradation of PD-1. **A**–**C**, PD-1+CTLA4+ double-positive CHO cells were pretreated with AF488-labeled MEDI5752, anti–PD-1, mvPD-1, anti-CTLA4, or mvCTLA4 mAbs at 4°C for 30 minutes. After washing to remove excess antibody, cells were incubated at 37°C to initiate internalization and imaged on Opera using 20× objective. Columbus software was used for image analysis. B, Total antibody binding was quantified as FL488 sum intensity mean per well. C, Antibody internalization was measured as intracellular spot FL488 sum intensity mean per well and divided by total antibody intensity to determine % antibody internalized (n = 3, independent experiments). **D** and **E**, Internalization of MEDI5752 and parental mAbs into CD4+ and CD8+ T cells stimulated with anti-CD3 and anti-CD28 mAbs. Internalization was determined by conjugation of the test and control antibody mAbs with a pH-reactive dye that fluorescence brightly only after internalization and trafficking into acidic intracellular compartments. F, PD-1-SNAP-tag/CTLA4-CLIP-tag double-positive CHO cells were prelabeled with SNAP-Cell 647 and CLIP-Cell 505. Cells were treated with MEDI5752, anti–PD-1, anti-CTLA4, mvPD-1, or mvCTLA4 mAbs and imaged over live time course at 37°C. G and **H**, PD-1 (G) and CTLA4 (H) receptor was quantified as FL647 (PD-1) or FL488 (CTLA4) sum intensity mean per well (n = 3, independent experiments). I, Human CD4+ T cells were stimulated with Phytohaemagglutinin in the presence of MEDI5752, anti–PD-1, anti-CTLA4, or a combination of anti–PD-1 and anti-CTLA4 mAbs for 24 hours. PD-1 and CTLA4 protein expression was analyzed by Western blot (n = 4, independent donors, representative blot shown). Each point represents the mean values of duplicate wells, and the ±SEM is represented by error bars.
treatment (Fig. 4B), it is likely MEDI5752 is not degraded, unlike PD-1. We next tested whether these findings were phenocopied on human NSCLC TILs treated with MEDI5752. Similarly, MEDI5752 induced profound downregulation of PD-1 in CD4+ FOXP3+ T cells compared with an isotype mAb control or a combination of anti–PD-1 and anti-CTLA4 mAbs (Supplementary Fig. S1A–S1C).

**MEDI5752 Preferentially Targets CTLA4 on Double-Positive Cells Compared with mAb Combination**

Next, the ability of MEDI5752 to preferentially target and saturate the CTLA4 receptor on CHO PD-1+ CTLA4+ cells was assessed (Fig. 5A and B). MEDI5752 saturated the CTLA4 receptor on CHO PD-1+ CTLA4+ (10:1) and CHO PD-1+ CTLA4+ (40:1) cells at approximately 10- and 250-fold lower concentration, respectively, compared with anti-CTLA4 mAb coadministered with anti–PD-1 mAb (Fig. 5B; Supplementary Fig. S9). Furthermore, there was no difference in the capacity of MEDI5752 to saturate the PD-1 receptor when compared with anti-CTLA4 mAb coadministered with anti–PD-1 mAb (Fig. 5B; Supplementary Fig. S9). Next, we tested the functional consequence of cooperative binding of MEDI5752 on anti-CD3/SEB stimulated PBMC. These data showed that cooperative binding of MEDI5752 reduces the MEC required to induce a 3-fold increase in IL2 secretion from baseline was calculated.

**MEDI5752 Preferentially Localizes to the Tumor and Inhibits Tumor Growth In Vivo**

Due to the lack of cross-reactivity of MEDI5752 with murine PD-1 and CTLA4, a novel transgenic mouse model expressing human PD-1 and human CTLA4 on immune cells (C57BL/6N–Pdcd1tm1hhuCtla4tm1hhu) was used to study the in vivo activity of MEDI5752. Biodistribution studies using radiolabeled molecules in mice bearing MCA205 tumors revealed that significantly higher levels of MEDI5752 localized to the tumor when compared with a conventional anti-CTLA4 or isotype mAb (Fig. 6A–D). For MEDI5752, we confirmed this tumor localization was a consequence of target binding, as no increase in tumor localization was observed in mice bearing wild-type PD-1/CTLA4 receptors. We observed no significant difference in tumor localization when comparing MEDI5752 with a conventional anti–PD-1 mAb. These data suggest that the biodistribution of the antibodies was dependent on PD-1 expression and binding. Moreover, this significant increase in tumor localization of MEDI5752 when compared with a CTLA4 mAb demonstrates the potential for enhanced blockade of the receptor in the TME. Furthermore, we showed strong, dose-dependent antitumor activity of MEDI5752 in this model, achieving complete tumor clearance in more than 60% of mice when administered at 10 mg/kg (Fig. 6E). When compared with monotherapy with anti–PD-1 or anti-CTLA4 mAb only, a single dose of MEDI5752, but not a combination of parental mAbs, led to increased survival (Fig. 6F). Moreover, in NOD/SCID gamma (NSG) mice infused with human viral–specific T cells bearing human viral peptide–transduced OE21 tumors, treatment with MEDI5752 inhibited tumor growth to a greater extent than a combination of parental mAbs (Fig. 6G). These data provide evidence that MEDI5752 can preferentially localize to the tumor when compared with a CTLA4 mAb, and provide improved efficacy when compared with conventional PD-1/CTLA4 mAbs.

**MEDI5752 Has Demonstrated Activity in Advanced Solid Tumors**

MEDI5752 is being evaluated in an ongoing first-time-in-human study in advanced solid tumors (NCT03530397). Here, we present preliminary data as illustrative evidence of clinical activity with a partial response with 60% tumor reduction in a 61-year-old patient with gastric adenocarcinoma who had failed five prior lines of chemotherapy (Fig. 7A) and a partial response with 68% tumor reduction in a 51-year-old patient with treatment-naive clear cell carcinoma of the kidney (Fig. 7B). Both remain progression-free at 80 and 24 weeks, respectively, with manageable toxicities.
Modulated CTLA4 Inhibition via Preferential Binding to PD-1

A
Anti-CTLA4
Anti–PD-1

CHO PD-1+/CTLA4+ (10:1)

Normalized % MFI

CHO PD-1+/CTLA4+ (40:1)

Normalized % MFI

CHO PD-1+/CTLA4+ (10:1)

Normalized % MFI

MEDI5752 binding

B
Unbound CTLA4 receptor
Unbound PD-1 receptor
Anti–PD-1 + anti-CTLA4

C
MEDI5752
Anti-CTLA4 + anti–PD-1
mvCTLA4 + anti–PD-1

D
MEDI5752 vs. anti-CTLA4 - 42.33 fold
MEDI5752 vs. mvCTLA4 - 96.35 fold

P = 0.0005
P = 0.0065

E
IFNγ secretion

F
IFNγ secretion - CD4

G
IFNγ secretion - CD8

Published Online First January 8, 2021; DOI: 10.1158/2159-8290.CD-20-1445
Isotype IgG

Anti–PD-1

Anti-CTLA4

MEDI5752

Tumor ex vivo gamma counting

Tumor imaging

MCA205 tumor model

MCA205 tumor model

OE21 10 × GS tumor model

Figure 6. MEDI5752 inhibits tumor growth in vivo and preferentially localizes to the tumor. A–F, Transgenic PD-1huKI/CTLA4huKI mice (or C57BL/6 wild-type control mice when indicated as WT) were subcutaneously implanted with MCA205 tumors. A and B, On day 15 after implantation, 89Zr-labeled MEDI5752, anti–PD-1, anti–CTLA4, and isotype mAbs were i.v. dosed (5 mice per group), and PET imaging was performed at 24, 48, 72, and 96 hours after dosing. Tracer uptake in the region of interest was normalized to blood tracer levels and plotted as meanSUV:blood ratio. Statistical significance was calculated using a mixed-effects model with Dunnett multiple comparisons test. C, Ninety-six hours after dosing, animals were sacrificed, and tissues were collected. Tracer uptake was quantified by gamma counting and expressed as the ratio of tissue to blood tracer levels. Statistical significance was calculated using a log-rank test and tissues were collected. Tracer uptake was quantified by gamma counting and expressed as the ratio of tissue to blood tracer levels. Statistical significance was calculated using a one-way ANOVA with Dunnett multiple comparison test. D, Ninety-six hours after dosing, animals were sacrificed, and tissues were collected. Tracer uptake was quantified by gamma counting and expressed as the ratio of tissue to blood tracer levels. Statistical significance was calculated using a mixed-effects model with Dunnett multiple comparisons test. E and F, For assessment of antitumor activity, mice were i.v. injected 5 or 6 days after tumor implantation with 10 mg/kg anti–CD20 antibody to deplete B cells. E, Mice were then i.p. injected with MEDI5752 or 10 mg/kg isotype mAb on days 7 and 11 after tumor implantation, and the relative tumor volume at day 19 after tumor implantation was calculated by dividing the difference in tumor volumes at days 19 and 7 by the tumor volume at day 19. Mice that had complete responses are marked with a diamond (8–10 mice per group). Data representative of 2 independent experiments. F, Mice were i.p. injected on day 11 after tumor implantation with 5 mg/kg MEDI5752, 5 mg/kg anti–PD-1, 5 mg/kg anti–CTLA4, a combination of 5 mg/kg anti–PD-1 and 5 mg/kg anti–CTLA4, or isotype mAb, and survival was monitored over time (6–8 mice per group). Statistical significance was calculated using a log-rank test. G, NSG mice were s.c. implanted with viral peptide-transduced OE21 tumor cells. On day 7 after tumor implantation, mice were i.v. injected with in vitro viral peptide-stimulated PBMC. 10 mg/kg MEDI5752, 10 mg/kg anti–PD-1, 10 mg/kg anti–CTLA4, a combination of 10 mg/kg anti–PD-1 and 10 mg/kg anti–CTLA4, or isotype mAbs were then i.p. injected on days 9, 11, 14, and 17 after tumor implantation, and tumor growth was monitored over time (10 mice per group, data representative of 2 independent experiments). Statistical significance was calculated using a mixed-effects model with Dunnett multiple comparisons test. P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Modulated CTLA4 Inhibition via Preferential Binding to PD-1

Moreover, we show that these PD-1+ CTLA4+ TILs also express CD8+ T cells at orders of magnitude lower concentrations than required to saturate CTLA4 on PD-1− cells. Molecular characterization of the Fc domain of MEDI5752 which incorporates three mutations to reduce effector function (41), thereby preventing depletion of effector populations critical for response.

CTLA4 can also be expressed on the surface of naïve T cells following signaling through the TCR and serves to attenuate T-cell activation. Clinical studies have demonstrated that CTLA4 blockade, presumably in secondary lymphoid organs, can increase the diversity of the peripheral TCR repertoire which is associated with both response and the onset of irAEs (37, 49). Interestingly, the stability of T-cell clonotypes present prior to the initiation of anti-CTLA4 mAb therapy has also been associated with improved survival in patients with cancer (37). It remains unclear how this peripheral change in TCR diversity/stability is influenced by CTLA4 blockade specifically on naïve T cells and/or on Treg cells, and moreover how this inhibition in the secondary lymphoid organs may contribute to antitumor activity. Furthermore, recent studies have demonstrated a confluence of the PD-1 and CTLA4 pathways with the identification that the reinvigoration of TILs following PD-1 blockade is dependent on CD28 costimulation (12, 13). These data suggest that concurrent blockade of the PD-1 and CTLA4 pathways on TILs may ultimately be needed to drive an optimal antitumor response. Consistent with this, tumor resident/infiltrating dendritic cell populations have been shown to be critical for supporting an inflamed TME (50) and for response to ICB (51). Importantly, several preclinical studies have also demonstrated that local blockade of CTLA4 within the tumor, and not the periphery, can facilitate immune-mediated tumor regressions (28–36). Taken together, these data support the hypothesis that directing CTLA4 inhibition to the TME may be sufficient to engender effective antitumor immune responses. In the TME, CTLA4 can function through the intrinsic pathway, directly affecting the cell expressing CTLA4. Alternatively, CTLA4 can function through the extrinsic pathway, indirectly affecting effector cell function via competition for/sequestration of available costimulatory ligands (21). Indeed, previous studies have demonstrated that inhibition of CTLA4 was required on both effector and regulatory compartments for maximal antitumor activity (18). We show that MEDI5752 can saturate CTLA4 on PD-1+ cells at orders of magnitude lower concentrations than required to saturate CTLA4 on PD-1− cells. Moreover, our data demonstrate that monovalent targeting of CTLA4 with either MEDI5752 or an mvCTLA4 is significantly less potent than bivalent targeting with a parental anti-CTLA4 mAb. In contrast, the switch to monovalent targeting of PD-1 has limited effect on potency. Together, these data demonstrate the capacity of MEDI5752 to preferentially inhibit CTLA4 on activated T cells (expressing PD-1) with significantly reduced activity on PD-1− T-cell populations. We hypothesize that these binding characteristics have the potential to provide enhanced CTLA4 blockade that can be achieved clinically with dual ICB.

Clinical data demonstrate a clear dose response for both efficacy and toxicity with CTLA4 inhibition (7, 8). However, our in vitro data demonstrate that conventional mAbs are far less able to saturate CTLA4 on primary T cells when compared with PD-1. We hypothesized this may be due to the rapid internalization and recycling kinetics associated with CTLA4, resulting in only a small fraction of the receptor presented on the cell surface at any given time (20, 24).

Figure 7. Tumor response induced by MEDI5752 and measured by a reduction in target lesion size compared with baseline (A) in a patient with gastric adenocarcinoma and (B) in a patient with clear cell carcinoma of the kidney.

DISCUSSION

Recent published studies demonstrate the innovation being applied to engineer improved antibody-based cancer immunotherapies as the field moves beyond conventional mAb (43–45). In this study, we describe the characterization of MEDI5752, a novel monovalent bispecific antibody designed to provide modulated CTLA4 engagement, favoring binding/inhibition on activated T cells expressing PD-1.

The contribution of Fc-mediated depletion of Treg by anti-CTLA4 mAbs remains contentious without clear evidence that this occurs in the clinic with ipilimumab or tremelimumab (46, 47). Our data demonstrate that CTLA4 expression is also enriched on PD-1+ CD4+ and CD8+ TILs and that on these cells PD-1 is expressed in excess of CTLA4. Moreover, we show that these PD-1+ CTLA4+ TILs also express CD39, a marker of antigen experience and exhaustion (39, 48), suggesting that these cells may be relevant contributor effectors of CTLA4-mediated antitumor activity. Moreover, this pattern of coexpression for CTLA4 and PD-1 underscores the design of the Fc domain of MEDI5752 which incorporates three mutations to reduce effector function (41), thereby preventing depletion of effector populations critical for response.

The rapid internalization and recycling kinetics associated with CTLA4, resulting in only a small fraction of the receptor presented on the cell surface at any given time (20, 24).

Clinical studies have demonstrated a confluence of the PD-1 and CTLA4 pathways on TILs may ultimately be needed to drive an optimal antitumor response. Consistent with this, tumor resident/infiltrating dendritic cell populations have been shown to be critical for supporting an inflamed TME (50) and for response to ICB (51). Importantly, several preclinical studies have also demonstrated that local blockade of CTLA4 within the tumor, and not the periphery, can facilitate immune-mediated tumor regressions (28–36). Taken together, these data support the hypothesis that directing CTLA4 inhibition to the TME may be sufficient to engender effective antitumor immune responses. In the TME, CTLA4 can function through the intrinsic pathway, directly affecting the cell expressing CTLA4. Alternatively, CTLA4 can function through the extrinsic pathway, indirectly affecting effector cell function via competition for/sequestration of available costimulatory ligands (21). Indeed, previous studies have demonstrated that inhibition of CTLA4 was required on both effector and regulatory compartments for maximal antitumor activity (18). We show that MEDI5752 can saturate CTLA4 on PD-1+ cells at orders of magnitude lower concentrations than required to saturate CTLA4 on PD-1− cells. Moreover, our data demonstrate that monovalent targeting of CTLA4 with either MEDI5752 or an mvCTLA4 is significantly less potent than bivalent targeting with a parental anti-CTLA4 mAb. In contrast, the switch to monovalent targeting of PD-1 has limited effect on potency. Together, these data demonstrate the capacity of MEDI5752 to preferentially inhibit CTLA4 on activated T cells (expressing PD-1) with significantly reduced activity on PD-1− T-cell populations. We hypothesize that these binding characteristics have the potential to provide enhanced CTLA4 blockade that can be achieved clinically with dual ICB.

Clinical data demonstrate a clear dose response for both efficacy and toxicity with CTLA4 inhibition (7, 8). However, our in vitro data demonstrate that conventional mAbs are far less able to saturate CTLA4 on primary T cells when compared with PD-1. We hypothesized this may be due to the rapid internalization and recycling kinetics associated with CTLA4, resulting in only a small fraction of the receptor presented on the cell surface at any given time (20, 24).
MEDI5752 leverages cross-arm avidity binding (where one of the fragment antigen-binding domains acts as an anchor for the other) to take advantage of both the more stable surface expression of PD-1 and the elevated cell-surface density of PD-1 versus CTLA4. Our data demonstrate enhanced saturation of CTLA4 with the PD-1/CTLA4 bispecific when compared with equimolar concentrations of a conventional mAb targeting CTLA4 and are consistent with recently reported data demonstrating the capacity of bispecific antibodies to promote improved target selectivity by cross-arm avidity binding to two antigens on the surface of the same cell (52–58). Moreover, we found that tethering PD-1 to CTLA4 also leads to the internalization and subsequent degradation of PD-1, providing a novel mechanism of action that is distinct from other mAbs targeting this axis. In the present study, we focused our observations on functional responses following treatment and did not assess changes in proximal signaling pathways. It is interesting to speculate that the degradation of PD-1 observed with MEDI5752 could potentially influence the dynamics of intracellular signaling when compared with conventional anti–PD-1 mAbs.

Supporting our in vitro observations, we further show that MEDI5752 preferentially localizes to the tumor when compared with a conventional anti-CTLA4 mAb and also provides improved efficacy in preclinical models when compared with a combination of PD-1 and CTLA4 mAbs that share the same specificities and intrinsic affinities. Although the biodistribution of MEDI5752 in the periphery was generally comparable to that of a conventional anti-CTLA4 mAb, we have demonstrated that CTLA4 inhibition is significantly reduced in the case of monovalent binding (on PD-1 T cells or vs. a conventional bivalent anti-CTLA4 mAb). Moreover, we present preliminary evidence illustrating the clinical activity of MEDI5752 from an ongoing first-time-in-human study of MEDI5752 in advanced solid tumors. These clinical data represent anecdotal evidence and should therefore be interpreted with caution. A multicenter phase I study is ongoing across a range of solid tumor types (NCT03530397) to examine the safety, pharmacokinetic/pharmacodynamic relationship, and efficacy of MEDI5752.

Modulating the inhibition of CTLA4 to favor blockade on PD-1+ T cells using a monovalent bispecific may provide a tractable method for directing CTLA4 blockade to antigen-experienced T cells. This approach may facilitate enhanced CTLA4 blockade beyond that achievable with current PD-1/PD-L1 and CTLA4 mAb combinations and has the potential to improve responses in tumors sensitive to dual checkpoint blockade and also open opportunities in tumor types where suboptimal exposures have prevented clinically meaningful activity.

**METHODS**

**Antibody Construction**

MEDI5752 was constructed on the backbone of the DuetMab molecule essentially as described (40). Briefly, the variable heavy (VH) and variable light (VL) genes of the anti-CTLA4 tremelimumab were inserted into a human gamma-1 constant heavy chain carrying the “Hole” mutations and a constant Kappa light chain, respectively. The VH and VL genes of an in-house anti–PD-1 mAb were inserted into a human gamma-1 constant heavy chain carrying the “Hole” mutations and a constant Kappa light chain, respectively. Collectively, the frameworks and complementarity determining regions for the PD-1 and CTLA4 mAbs were identical to those incorporated in MEDI5752. The Fc domain was further engineered to carry the triple mutations (L234F, L235E, and P331S) designed to reduce Fc-mediated immune effector functions (41). For the construction of mCTLA4 and mpPD-1 antibodies, the VH and VL genes of the anti-CTLA4 and anti–PD-1 mAbs were paired with the VH and VL genes of an isotype control to form heterodimer mCTLA4 and mpPD-1 antibodies, respectively.

**Concurrent Biochemical Binding**

Concurrent binding studies to recombinant human and cynomolgus monkey PD-1 and CTLA4 proteins were measured by biolayer interferometry on an Octet384 instrument (Fortebio). Biotinylated human PD-1 protein at 5 μg/mL in assay buffer [PBS pH 7.2, 3 mg/mL BSA, and 0.05% (v/v) Tween 20] was captured on streptavidin (SA) biosensors (Fortebio). Cynomolgus monkey PD-1–FLAG/10 HIS protein at 5 μg/mL in assay buffer was captured on anti-Penta HIS (HS1K) biosensors (Fortebio). Following a washing step to remove any unbound protein, the respective loaded biosensors were subjected to successive association and dissociation interactions, first with 5 μg/mL of MEDI5752 and then with human or cynomolgus monkey CTLA4 antigen at 5 μg/mL. Association and dissociation curves were calculated from a nonlinear fit of the data using the Octet384 software v.9.0.

**Concurrent Binding to Cell–Surface Receptors**

To determine concurrent binding of PD-1 and CTLA4 receptors by cell-bound MEDI5752, CHO PD-1+CTLA4+ and CHO PD-1+CTLA4− (10:1) were incubated with 3-fold serial dilutions of MEDI5752 or parental anti-PD-1 mAb starting at a concentration of 6.7 nmol/L for 30 minutes at 4°C. After washing with FACS buffer, cell-bound antibodies were detected by phycoerythrin (PE)-conjugated goat anti-human Fcγ antibody (Jackson ImmunoResearch), and free antigen-binding arms were detected by biotinylated soluble CTLA4 and PD-1 proteins at 5 nmol/L followed by SA–allophycocyanin (BioLegend). After incubation for 30 minutes at 4°C, cells were washed and fixed with 4% paraformaldehyde (PFA) for 10 minutes. Fluorescence detection of cell-bound IgG (PE) and monovalent binding to soluble antigens (allophycocyanin) was determined using an LSRII flow cytometer (BD Biosciences). Data analysis was performed using the FlowJo software, and the mean fluorescence intensity (MFI) was used to determine binding intensity. Based on physical properties (height, width, and density), only single cells were gated for analysis. All data analyses were performed using GraphPad Prism version 7.02 for Windows (GraphPad Software).

**Cellular Cooperative Binding Analyses**

Cooperative binding assays were performed by flow cytometry using a MACSQuant VYB (Miltenyi Biotec) instrument. To allow unbound receptor detection, parental anti-PD-1 and anti–CTLA4 mAbs were labeled with Alexa Fluor 647 and Alexa Fluor 488 labeling kits (Invitrogen), respectively, according to the manufacturer’s instructions. Antibody concentration and fluorochrome to protein (F/P) ratio was calculated by a ND-1000 spectrophotometer (NanoDrop). Antibody cell-binding and receptor occupancy were determined simultaneously. CHO PD-1 CTLA4+, CHO PD-1′CTLA4+ (10:1), and CHO PD-1′CTLA4− (40:1) cell lines at 2 × 10^5 viable cells/well were first washed with ice-cold assay buffer (PBS pH 7.2 with 1% FBS) and then incubated with 3-fold serial dilutions of unconjugated antibodies or a combination of unconjugated anti–PD-1 + anti–CTLA4 mAbs. After incubation for 30 minutes at 4°C, cells were washed and fixed with 4% PFA for 5 minutes. Unbound PD-1 receptor was detected with 15 μg/mL of anti–PD-1-Alexa Fluor 647 conjugate, whereas unbound CTLA4 receptor was detected using 15 μg/mL of anti–CTLA4-Alexa Fluor 488 conjugate. For the detection of cell-bound unconjugated...
antibodies, BV421-conjugated mouse anti-human IgG Fc (BioLegend) was used. The amount of antibodies bound to the cell surface was determined using MACSQuantify software. Data analysis was performed using the FlowJo software, and the MFI was used to determine binding intensity. Based on physical properties (height, width, and density), only single cells were gated for analysis. Bound antibody signal was normalized between maximal MFI signal at the highest concentration tested and signal in a no-antibody control. Unbound receptor signal was normalized between the maximal signal in a no-antibody control and signal obtained with 15 μg/mL of labeled IgGs, which was far above the concentration required for saturating fully internalized cell-surface antigen levels. All data analyses were performed using GraphPad Prism version 7.02 for Windows (GraphPad Software).

**Human Treg Suppression Assay**

CD4+ CD25+ CD127low human Treg (Donor 1) were isolated (StemCell Technologies) and 1 × 10⁶ cells were expanded for 6 days in differentiation medium [X-Vivo 15 media (Lonza) supplemented with 5% human serum, 1% penicillin–streptomycin, 5 × 10⁻³ CD3/CD28 activation beads (Thermo Fisher Scientific), and 100 IU IL2 (Corning)]. At day 6, Treg were harvested, washed with PBS, and rested for 24 hours in X-Vivo 15 media supplemented with 5% human serum and 1% penicillin–streptomycin. At day 7, allogeneic responder T cells (Donor 2) and T cell–depleted PBMC (Donor 3) were isolated (Stemcell). Treg and responder T cells were stained with CellTrace Violet and carboxyfluorescein succinimidyl ester proliferation dyes respectively (Thermo Fisher Scientific) and resuspended in assay medium (RPMI-1640 Glutamax I culture media supplemented with 10% FBS and 1% penicillin–streptomycin) to 1 × 10⁶ cells/mL. T cell–depleted PBMC were resuspended in assay medium to 2 × 10⁶ cells/mL 5 × 10⁴ responder T cells and 1 × 10⁵ T cell–depleted PBMC were added to each well, and 5 × 10⁴ Treg were titrated 1 in 2 across a 96-well round-bottomed tissue culture–treated plate. 1 μmol/L of MEDI5752, anti-CD1, anti-CTLA4, a combination of anti-CD1 and anti-CTLA4, or an isotype mAbs were added to cultures with 1 μg/mL anti-CD3 antibody (clone OKT3, BioLegend) alone or in combination with 5 μg/mL anti-CD28 antibody (clone 28.2, BioLegend) were incubated with serial dilutions of control and test antibodies, starting at a concentration of 180 nmol/L. Cells were added at 5 × 10⁴ and 1 × 10⁵ cells/well for CHO and primary CD3+ T cells, respectively, followed by incubation at 37°C with 5% CO₂ for time intervals of 3 hours for CHO cells and 4 hours for primary CD3+ T cells. For Time 0 control (background), cells were incubated at 4°C for 30 minutes. After incubation, cells were washed with FACS buffer to remove excess antibody, and CHO cells were fixed in 4% PFA prior to analysis using an LSR II flow cytometer (BD Biosciences). Primary CD3+ T cells were additionally costained with anti-CD4 (clone RPA-T4, BioLegend) and anti-CD8 (clone RPA-T8, BioLegend) antibodies, and a viability dye (4',6-diamidino-2-phenylindole or propidium iodide, Sigma) was used to discern each live population. Cells were kept on ice until analysis using the LSR II. Data analysis was performed using the FlowJo software, and the MFI was used to determine antibody internalization. All data analyses were performed using GraphPad Prism version 7.02 for Windows (GraphPad Software).

**PD-1 Receptor Downregulation Analyses**

To determine the effect of antibody internalization on surface PD-1 levels, CHO PD-1-CTL4+ (10:1) or primary CD3+ T cells stimulated with 1 μg/mL of anti-CD3 antibody (clone OKT3, BioLegend) alone or in combination with 5 μg/mL anti-CD28 antibody (clone 28.2, BioLegend) were incubated with serial dilutions of control and test antibodies, starting at a concentration of 180 nmol/L. Cells were added at 5 × 10⁴ and 1 × 10⁵ cells/well for CHO and primary CD3+ T cells, respectively, followed by incubation at 37°C with 5% CO₂ for time intervals noted. For Time 0 controls, cells were incubated at 4°C for 30 minutes. After incubation, cells were washed twice with FACS buffer to remove excess antibody, and residual surface PD-1 receptor was detected by incubation with 50 μg/mL of a noncompeting anti-PD-1 antibody labeled with allophycocyanin at 4°C for 30 minutes. Primary CD3+ T cells were additionally costained with fluorescently labeled anti-CD4 (clone RPA-T4, BioLegend) and anti-CD8 (clone RPA-T8, BioLegend) antibodies, in addition to propidium iodide (Sigma) to exclude dead cells. After staining, CHO cells were fixed with 4% PFA for 10 minutes, and T cells were kept on ice until analysis using an LSR II flow cytometer (BD Biosciences). Data analysis was performed using the FlowJo software, and residual cell-surface PD-1 was measured as the MFI of allophycocyanin signal. All data analyses were performed using GraphPad Prism version 7.02 for Windows (GraphPad Software).

**Receptor Tracking by High Content Imaging**

Receptor PD-1+ SNAP-tag/CTLA4+ CLIP-tag double-positive CHO cells were labeled with 2 μmol/L Cell Tracker red CMTPX, plated at 2 × 10⁶ cells/well in a 96-well plate, and incubated overnight at 37°C. Receptors were preincubated with SNAP-Cell 647 and CLIP-Cell 505 according to the manufacturer’s instructions (New England Bio Labs). Briefly, cells were incubated with 1:200 SNAP-Cell 647 and 1:200 CLIP-Cell 505 in complete media at 37°C for 60 minutes. After three washes, cells were incubated with 2 μg/mL Hoechst for 30 minutes. After three washes, cells were resuspended in complete media. Immediately after addition of 40 nmol/L MED15752, anti-PD-1, anti-CTLA4, or mAb treatment, cells were imaged. This staining procedure was used for total PD-1+ receptor and CTLA4 receptor turnover quantitation and colocalization analysis.

**PD-1 Receptor, CTLA4 Receptor, and Lysosome Colocalization**

Receptor PD-1+ SNAP-tag/CTLA4+ CLIP-tag double-positive CHO cells were labeled with 20 μmol/L Cell Tracker blue CMAC (Molecular Probes), plated at 2 × 10⁶ cells/well in a 96-well plate, and incubated...
overnight at 37°C. The next day, cells were incubated with 1:200 SNAP-Cell TMR, 1:200 CLIP-Tag/Cell 505, and 50 nmol/L LysoTracker Red (Invitrogen) in complete media at 37°C for 60 minutes. After three washes, cells were resuspended in complete media. Immediately after addition of 40 nmol/L Alexa Fluor 488-labeled MEDI5752 or 40 nmol/L Alexa Fluor 488-labeled anti-PD-1 mAb treatment, cells were imaged.

**PD-1 Receptor, Drug, andlysosome Co-localization**

Receptor PD-1-SNAP-tag/CTLA4-CLIP-tag double-positive CHO cells were labeled with 20 µmol/L Cell Tracker blue CMAC, plated at 2 × 10⁵ cells in a 96-well plate, and incubated overnight at 37°C. The next day, cells were incubated with 1:200 SNAP-Cell TMR and 50 nmol/L LysoTracker Red (Invitrogen) in complete media at 37°C for 60 minutes. After three washes, cells were resuspended in complete media. Immediately after addition of 40 nmol/L Alexa Fluor 488-labeled MEDI5752 or 40 nmol/L Alexa Fluor 488-labeled anti-PD-1 mAb treatment, cells were imaged.

**MCA205 Tumor Model**

Antitumor activity of MEDI5752 was assessed in a novel transgenic mouse strain generated by genOway that expresses human PD-1 and CTLA4 instead of the murine proteins (C57BL/6N-Pdcd1 tm1(C57BL/6N-ICP13)Geno CtlA4tm1(C57BL/6N-ICP13)Geno). This mouse strain was developed by intercrossing the human PD-1 (C57BL/6N-Pdcd1 tm1(C57BL/6N-ICP13)Geno) and the human CTLA4 (C57BL/6N-CtlA4tm1(C57BL/6N-ICP13)Geno) mouse strains. Briefly, the human PD-1 strain was developed by inserting within the mouse PD-1 locus a chimeric PD-1 with a human extracellular domain and murine transmembrane and intracellular domains. Similarly, the human CTLA4 strain was developed by inserting within the mouse CTLA4 locus a chimeric CTLA4 with a human extracellular domain and murine transmembrane and intracellular domains. For both strains, homologous recombination was performed in C57BL/6N-derived embryonic stem cells, and mouse chimeras were bred with Cre (for the human PD-1 strain) and Flp (for the human CTLA4 strain) delete mice to excise the neo/myc selection cassette and generate heterozygous mice carrying the Neo/exonuclease humanized knock-in alleles. The mice were bred at Charles River France, supplied at 6 to 8 weeks of age, and housed under specific pathogen-free conditions in Tecniplast Green Line IVC Sealsafe cages holding a maximum of six animals with irradiated aspen chip bedding, Nestlets nesting material, a cardboard tunnel, and wooden chew blocks. Mice were housed on a 12/12 light/dark cycle, with ad libitum UV-treated water and RM1 rodent diet. 100 µL containing 5 × 10⁶ MCA205 cells in 50% growth factor-reduced Matrigel (Corning) containing 5 µg/ml influenza A–derived peptides, and one CMV-derived peptide) were s.c. injected into the flank of NSG mice (The Jackson Laboratory). All animals were housed per Institutional Animal Care and Use Committee–approved protocols in the Laboratory Animal Resources facility, an Association for Animal Accreditation of Laboratory Animal Care and United States Department of Agriculture-licensed facility. The animals were kept in sterile microisolator units, provided with sterile bedding and food, and acidified drinking water ad libitum. Environmental conditions were standardized (room temperature: 20°C ± 1°C; relative humidity: 50% ± 10%; 12-hour light–dark cycle). Seven days after tumor implantation, mice were i.p. injected with 1 × 10⁶ peptide-stimulated antigen-specific CD8+ T cells and then p.i. injected with 10 mg/kg MEDI5752, anti-PD-1, anti-CTLA4, or an isotype IgG on days 9, 11, and 14, and 17 after tumor implantation. Two to 3 hours prior to this treatment, mice were i.p. injected with a combination of 100 mg/kg GammaGard (Shire Labs) and 20 mg/kg of anti-mouse CD16/CD32 (BioXCell). PBMC were obtained from healthy donors and prescreened for HLA haplotype and viral peptide reactivity in accordance with the Declaration of Helsinki, with donors signing a written informed consent before sample collection.

**Clinical Study**

The first-time-in-human clinical study (NCT03530397) was approved by appropriate Institutional Review Boards at each participating site and conducted in accordance with Good Clinical Practice guidelines and the ethical principles of the Declaration of Helsinki. All patients provided written informed consent. Escalating doses of MEDI5752 were administered i.v. Safety was assessed using CTCAE v4.03. Response assessment was done utilizing RECISTv1.1. The study is ongoing.

**Statistical Analysis**

In two-cell reporter assays, potency was determined by generating EC₅₀ values using a nonlinear regression model (log agonist vs. response – variable slope (four parameters)). Statistical significance was assessed using a two-tailed Student's t-test.
for MEDI5752 versus control groups in primary human anti-CD3/SEB assays was determined using a paired t test and in Treg suppression assays was determined using a two-way ANOVA with Dunnett multiple comparisons post test. Statistical significance for MEDI5752 versus control groups was determined for tumor imaging and tumor volume using a mixed-effects model with the Geisser–Greenhouse correction and for gamma counting using an ordinary one-way ANOVA, both with Dunnett multiple comparisons testing. For survival analysis, statistical significance was determined using the log-rank test, and for the dose-dependent effects of MEDI5752 on tumor volume, statistical significance was determined using a mixed-effects model with the Geisser–Greenhouse correction and Tukey multiple comparisons testing. For all tests, significance was determined with a 95% confidence interval (P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001) on GraphPad Prism, version 8.

Authors’ Disclosures

S.J. Dovedi reports personal fees from AstraZeneca during the conduct of the study and outside the submitted work; in addition, S.J. Dovedi has a patent for 10,457,732 issued to AstraZeneca. M.J. Elder reports being an AstraZeneca employee outside the submitted work. J. Hair reports personal fees and other support from AstraZeneca Ltd. during the conduct of the study. S.-A. Im reports grants and other support from AstraZeneca, Eisai, Pfizer, and Roche; other support from Amgen, Lilly, Hanni, MSD, and Novartis; and grants from Daewoong outside the submitted work. B. Tran reports other support from AstraZeneca during the conduct of the study; and grants and personal fees from Amgen, AstraZeneca, Astellas, BMS, Janssen, Pfizer, MSD, Ipsen, and Bayer, and personal fees from IQVIA, Sanofi, Tolmar, Novartis, and Roche outside the submitted work. D.S. Subramaniam reports other support from AstraZeneca Plc during the conduct of the study. S.D. Gainer reports other support from GlaxoSmithKline and Novartis, and personal fees and other support from AstraZeneca outside the submitted work. K. Vashishtha reports being employee of AstraZeneca and receiving compensation from them. A. Lewis reports other support from AstraZeneca during the conduct of the study and outside the submitted work. Y. Wang reports personal fees from AstraZeneca outside the submitted work. M.G. Overstreet reports personal fees from Acra Biosciences outside the submitted work. J. Dodgson reports personal fees from AstraZeneca outside the submitted work. M. Morrow reports other support from F-star Therapeutics outside the submitted work; in addition, M. Morrow has a patent for US 10,457,732 issued. G.J. Rainey reports other support from Gritstone Oncology, Immetis Therapeutics, Life Biosciences, and Malbax Therapeutics Holdings, Inc., and personal fees from Cambridge Healthtech Institute outside the submitted work; in addition, G.J. Rainey has a patent for bispecific binding proteins and uses thereof issued. G.J. Browne reports other support from AstraZeneca during the conduct of the study and outside the submitted work. Y. Wang reports personal fees from AstraZeneca outside the submitted work. M.G. Overstreet reports personal fees from AstraZeneca outside the submitted work. J. Hair reports personal fees and other support from AstraZeneca during the conduct of the study and outside the submitted work. W. Dall’Acqua reports working for, and receiving a salary from, AstraZeneca. I. Achour reports other support from AstraZeneca during the conduct of the study and outside the submitted work. D.J. Freeman reports personal fees from AstraZeneca during the conduct of the study and outside the submitted work; in addition, D.J. Freeman reports being a full-time employee and shareholder of AstraZeneca. R.W. Wilkinson reports other support from AstraZeneca during the conduct of the study and outside the submitted work. No disclosures were reported by the other authors.

Authors’ Contributions


Acknowledgments

The authors would like to thank Janette Dillon, Emily Dick, and Natalie Tigue for generating the CHO K1 OKT3-CD14 (low) bH7H1 (high) cl 2 cells.

Received October 13, 2020; revised December 4, 2020; accepted December 17, 2020; published first January 8, 2021.

REFERENCES

Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1 + Activated T Cells

Simon J. Dovedi, Matthew J. Elder, Chunning Yang, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/2159-8290.CD-20-1445

Supplementary Material
Access the most recent supplemental material at:
http://cancerdiscovery.aacrjournals.org/content/suppl/2021/01/05/2159-8290.CD-20-1445.DC1
http://cancerdiscovery.aacrjournals.org/content/suppl/2021/04/26/2159-8290.CD-20-1445.DC2

Cited articles
This article cites 59 articles, 23 of which you can access for free at:
http://cancerdiscovery.aacrjournals.org/content/11/5/1100.full#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
http://cancerdiscovery.aacrjournals.org/content/11/5/1100.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerdiscovery.aacrjournals.org/content/11/5/1100.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.